Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline

On October 15, 2025 Jacobio Pharma (1167.HK) reported that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry partner. Under the agreement, Oceanpine Capital will acquire 80% equity interest in Beijing Jacoray Pharmaceutical Technology Co., Ltd. ("Jacoray") for a total consideration of RMB 200 million (comprising RMB 125 million as the upfront payment and an additional RMB 75 million as a second instalment milestone payment). Upon completion, Beijing Jacobio, Oceanpine Capital, and the industry partner will hold 10%, 80%, and 10% of Jacoray, respectively.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jacoray is the project company for Jacobio’s early-stage cardiovascular research program. The transaction aligns with Jacobio’s strategic focus on developing innovative oncology therapies—including KRAS and iADC —by optimizing capital allocation, enhancing operational efficiency, and adopting a risk-sharing model to retain long-term project value. Proceeds from the transaction will primarily support R&D, production, and commercialization of Jacobio’s Pan-KRAS inhibitor and other oncology assets.

Mr. Dave Chenn, Founder, CEO and Managing Partner of Oceanpine Capital, said: "Jacobio demonstrates outstanding scientific strength and strategic focus in oncology innovation. Oceanpine Capital looks forward to partnering with Jacobio to advance the globalization of China’s biotech innovation."

Dr. Yinxiang Wang, Chairman of Jacobio, said, "This partnership with Oceanpine Capital strengthens our strategic focus on oncology innovation and reinforces our commitment to advancing next-generation cancer therapies."

(Press release, Jacobio Pharmaceuticals, OCT 15, 2025, View Source [SID1234656679])